Undercovered Dozen: BrightSpire Capital, Vertex Pharmaceuticals, Adobe And More
This week's Undercovered Dozen spotlights 12 lesser-known stocks and ETFs, offering unique investment opportunities across gold, biotech, income, and tech sectors. B2Gold and Vertex Pharmaceuticals stand out as strong buys, driven by robust fundamentals, sector leadership, and clear growth catalysts for 2025 and beyond. Caution is urged on popular income-focused ETFs like SPYI and ULTY, as structural flaws and capped upside may limit long-term wealth compounding.
Vertex Inc.: Moving To The Sidelines As Near-Term Growth Expectations Get Reset
I downgrade Vertex (VERX) to Hold due to macro headwinds and ERP migration delays impacting near-term growth outlook. Cloud momentum and e-invoicing adoption remain strong, but on-premise weakness and slower customer expansion weigh on results. FY25 guidance was cut, and growth reacceleration is now less certain, resetting investor expectations and hurting sentiment.
Vertex Pharmaceuticals Is A Strong Buy After The Recent Pullback (Upgrade)
The recent Vertex Pharmaceuticals Incorporated stock drop after VX-993 trial results is overblown; the pain franchise remains robust with multiple promising avenues and ongoing trials. Vertex's CF franchise remains a dominant, reliable growth engine, with new revenue ramps from Casgevy and Journavx set to accelerate diversification. VRTX stock valuation is attractive: forward P/E is favorable versus peers, growth prospects are strong, and insider buying signals management confidence at current prices.
Here's What Key Metrics Tell Us About Vertex (VERX) Q2 Earnings
Although the revenue and EPS for Vertex (VERX) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Vertex (VERX) Q2 Earnings and Revenues Surpass Estimates
Vertex (VERX) came out with quarterly earnings of $0.15 per share, beating the Zacks Consensus Estimate of $0.14 per share. This compares to earnings of $0.15 per share a year ago.
Vertex Pharmaceutical Stock Dives as Firm to Stop Developing Acute Pain Drug
Shares of Vertex Pharmaceuticals (VRTX) sank 15% Tuesday, a day after the drugmaker announced a study showed its experimental pain medicine was not successful, and it would no longer move forward with its development.
Vertex (VERX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Vertex (VERX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Vertex Gears Up to Report Q2 Earnings: Is a Beat in the Cards?
VRTX eyes second-quarter growth with surging Trikafta sales. Investors' focus is likely to be on the progress of Casgevy, and Alyftrek and Journavx launches.
Will Vertex (VERX) Beat Estimates Again in Its Next Earnings Report?
Vertex (VERX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Vertex (VERX) Moves 5.0% Higher: Will This Strength Last?
Vertex (VERX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Vertex: Latest Casgevy Data Highlights Efficacy Amid Slow Commercial Launch
Vertex Pharmaceuticals Incorporated remains a Buy: its cystic fibrosis franchise ensures robust revenue for a decade, and its pipeline offers multiple long-term growth drivers. Casgevy's long-term data shows durable, life-changing benefits for SCD and TDT patients, but adoption is limited by a complex, intensive treatment process. Current Casgevy revenues are modest, but improvements to preconditioning and in-vivo approaches could unlock blockbuster potential by 2030.
Vertex Gets EU Nod for New Cystic Fibrosis Drug Alyftrek
VRTX secures EU approval for Alyftrek, a next-in-class triple combination regimen for treating people with CF aged six years and older.
